CDK2

cyclin dependent kinase 2

Explore in graph →CI-GENE-00040727HGNC:1771 ENSG00000123374 NCBI 1017 CIViC Approved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CDK2 CYTOPLASMIC EXPRESSION1
Carboplatin + EribulinCombination	Triple-Negative Breast CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	submitted	EID2969 In a Phase 2 trial, HRD score, HR deficiency status, and cytoplasmic CDK2 predicted pathologic complete remission to neoadjuvant therapy with carboplatin and eribulin in early stage TNBC patients. PMID 26006067 · Kaklamani et al., 2015 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (1)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved1 cohort row · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Triple-Negative Breast Cancer (FUSCC, Cell Research 2020) brca_fuscc_2020	Invasive Breast Carcinoma	Ssm	1

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.